Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022.
The post Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition appeared first on MedCity News.